Division of hematology / oncology

Carolyn D. Britten, M.D.

Associate Professor

Dr. Britten is the new Phase I Director of the Clinical Trials Program at the Hollings Cancer Center. She is joining the Hematology/Oncology faculty from the University of California at Los Angeles where she was an Associate Clinical Professor and headed up phase 1 clinical trials for almost 12 years.  She received her Medical Degree from the University of Toronto in 1992. She then went on to complete two fellowships, one in medical oncology at the University of British Columbia at Vancouver and one in drug development at the University of Texas at San Antonio. Dr. Britten's clinical focus is Gastrointestinal Oncology.

In Phase I trials, researchers test an experimental drug or treatment for the first time in a small group of patients (20-80) to evaluate its safety, determine a safe dosage range, and identify side effects. Dr. Britten's appointment to Phase 1 Director of Clinical Trials will mean the acceleration of phase 1 trials at MUSC's Hollings Cancer Center and a greater availability of cutting-edge therapies to patients with cancer in South Carolina and neighboring states.

More on Dr. Britten



Carolyn D. Britten, M.D.

Dr. Britten's Research Interests

  • Phase I clinical trials
  • Developmental Cancer Therapeutics
 
 
 

© Medical University of South Carolina | 171 Ashley Avenue, Charleston, SC 29425